LabGenomics files patent for AI medical platform 'Messemble'... "Leading early cancer diagnosis market"

LabGenomics announced on the 13th that it has completed a patent application for 'Mesemble,' a user-customized cancer disease analysis platform based on AI. Through Mesemble, the company plans to accelerate the development of liquid biopsy-based cancer diagnostic biomarkers.

Mesemble, developed by its subsidiary XenocoreBS, is a platform name combining DNA Methylation and Assemble. It predicts cancer occurrence by analyzing DNA methylation patterns of cancer patients and normal groups based on epigenomic information of cancer diseases. The accumulated data from this process can be utilized to discover liquid biopsy-based cancer diagnostic biomarkers.

Previously, biomarker development targeted genes through experimental and functional methods based on academic papers. Mesemble uses AI analysis technology to select biomarkers that improve cancer diagnostic accuracy and enhance commercialization potential. LabGenomics has already secured significant data targeting diseases that are difficult to diagnose early, such as prostate cancer, pancreatic cancer, ovarian cancer, and dementia, using Mesemble. Additionally, it has discovered biomarkers optimized for early diagnosis of prostate cancer and is currently conducting validation experiments.

A company representative stated, "We will complete experiments verifying the accuracy data of the secured biomarkers within this year," adding, "Sequential validation experiments will also begin for pancreatic cancer, ovarian cancer, Alzheimer's dementia, and others." They emphasized, "Based on meaningful validation result data, we will enhance the completeness of the patent and lead the early cancer diagnosis market."

This content was produced with the assistance of AI translation services.